Published in J Neurosci on July 28, 2004
Toll-like receptor-mediated cytokine production is differentially regulated by glycogen synthase kinase 3. Nat Immunol (2005) 7.13
Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics. Neurochem Res (2006) 3.12
Glycogen synthase kinase 3: more than a namesake. Br J Pharmacol (2009) 2.77
Lrp5-independent activation of Wnt signaling by lithium chloride increases bone formation and bone mass in mice. Proc Natl Acad Sci U S A (2005) 2.67
GSK-3: Functional Insights from Cell Biology and Animal Models. Front Mol Neurosci (2011) 1.99
Lithium nephrotoxicity revisited. Nat Rev Nephrol (2009) 1.92
Is glycogen synthase kinase-3 a central modulator in mood regulation? Neuropsychopharmacology (2010) 1.87
Glycogen synthase kinase-3 (GSK3) in psychiatric diseases and therapeutic interventions. Curr Drug Targets (2006) 1.78
Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases. Pharmacol Ther (2014) 1.77
Deletion of GSK-3beta in mice leads to hypertrophic cardiomyopathy secondary to cardiomyoblast hyperproliferation. J Clin Invest (2008) 1.76
Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo. Blood (2007) 1.75
Mood disorder susceptibility gene CACNA1C modifies mood-related behaviors in mice and interacts with sex to influence behavior in mice and diagnosis in humans. Biol Psychiatry (2010) 1.70
Combined treatment with the mood stabilizers lithium and valproate produces multiple beneficial effects in transgenic mouse models of Huntington's disease. Neuropsychopharmacology (2011) 1.66
What Are the bona fide GSK3 Substrates? Int J Alzheimers Dis (2011) 1.65
The role of lithium in the treatment of bipolar disorder: convergent evidence for neurotrophic effects as a unifying hypothesis. Bipolar Disord (2009) 1.62
Deficiency in the inhibitory serine-phosphorylation of glycogen synthase kinase-3 increases sensitivity to mood disturbances. Neuropsychopharmacology (2010) 1.61
Synergistic neuroprotective effects of lithium and valproic acid or other histone deacetylase inhibitors in neurons: roles of glycogen synthase kinase-3 inhibition. J Neurosci (2008) 1.58
Therapeutic potential of mood stabilizers lithium and valproic acid: beyond bipolar disorder. Pharmacol Rev (2013) 1.52
Glycogen synthase kinase-3 in the etiology and treatment of mood disorders. Front Mol Neurosci (2011) 1.48
GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS. Front Mol Neurosci (2011) 1.47
Targeting protein kinases in central nervous system disorders. Nat Rev Drug Discov (2009) 1.45
Modeling the positive symptoms of schizophrenia in genetically modified mice: pharmacology and methodology aspects. Schizophr Bull (2009) 1.45
Abnormalities in brain structure and behavior in GSK-3alpha mutant mice. Mol Brain (2009) 1.44
Genetic deficiency of glycogen synthase kinase-3beta corrects diabetes in mouse models of insulin resistance. PLoS Biol (2008) 1.40
Lithium ameliorates altered glycogen synthase kinase-3 and behavior in a mouse model of fragile X syndrome. Biochem Pharmacol (2010) 1.39
Molecular actions and therapeutic potential of lithium in preclinical and clinical studies of CNS disorders. Pharmacol Ther (2010) 1.39
GSK-3 is a viable potential target for therapeutic intervention in bipolar disorder. Neurosci Biobehav Rev (2007) 1.36
GSK-3 and Wnt Signaling in Neurogenesis and Bipolar Disorder. Front Mol Neurosci (2012) 1.34
Elevated glycogen synthase kinase-3 activity in Fragile X mice: key metabolic regulator with evidence for treatment potential. Neuropharmacology (2008) 1.28
Review of pharmacological treatment in mood disorders and future directions for drug development. Neuropsychopharmacology (2011) 1.28
Validating GSK3 as an in vivo target of lithium action. Biochem Soc Trans (2009) 1.27
GSK3beta is a negative regulator of platelet function and thrombosis. Blood (2008) 1.27
Antidepressant effects of ketamine: mechanisms underlying fast-acting novel antidepressants. Front Pharmacol (2013) 1.25
Novel insights into lithium's mechanism of action: neurotrophic and neuroprotective effects. Neuropsychobiology (2010) 1.25
Bipolar disorder: from genes to behavior pathways. J Clin Invest (2009) 1.24
Glycogen synthase kinase-3 is essential for β-arrestin-2 complex formation and lithium-sensitive behaviors in mice. J Clin Invest (2011) 1.20
Wnt signaling in the vertebrate central nervous system: from axon guidance to synaptic function. Cold Spring Harb Perspect Biol (2012) 1.18
Targeting the glutamatergic system to treat major depressive disorder: rationale and progress to date. Drugs (2012) 1.17
Involvement of AMPA receptors in the antidepressant-like effects of lithium in the mouse tail suspension test and forced swim test. Neuropharmacology (2007) 1.16
GSK-3 as a Target for Lithium-Induced Neuroprotection Against Excitotoxicity in Neuronal Cultures and Animal Models of Ischemic Stroke. Front Mol Neurosci (2011) 1.14
Inhibition of GSK3 by lithium, from single molecules to signaling networks. Front Mol Neurosci (2012) 1.14
Animal models of bipolar disorder and mood stabilizer efficacy: a critical need for improvement. Neurosci Biobehav Rev (2007) 1.13
DISC1: Structure, Function, and Therapeutic Potential for Major Mental Illness. ACS Chem Neurosci (2011) 1.13
The behavioral actions of lithium in rodent models: leads to develop novel therapeutics. Neurosci Biobehav Rev (2007) 1.12
A role for Akt and glycogen synthase kinase-3 as integrators of dopamine and serotonin neurotransmission in mental health. J Psychiatry Neurosci (2012) 1.12
A kinesin signaling complex mediates the ability of GSK-3beta to affect mood-associated behaviors. Proc Natl Acad Sci U S A (2010) 1.11
Generation and behavioral characterization of beta-catenin forebrain-specific conditional knock-out mice. Behav Brain Res (2008) 1.10
AKT kinase activity is required for lithium to modulate mood-related behaviors in mice. Neuropsychopharmacology (2011) 1.08
Lithium rescues synaptic plasticity and memory in Down syndrome mice. J Clin Invest (2012) 1.07
Synaptic Wnt signaling-a contributor to major psychiatric disorders? J Neurodev Disord (2011) 1.06
Predictive animal models of mania: hits, misses and future directions. Br J Pharmacol (2011) 1.04
Selective deletion of forebrain glycogen synthase kinase 3β reveals a central role in serotonin-sensitive anxiety and social behaviour. Philos Trans R Soc Lond B Biol Sci (2012) 1.02
Association study of Wnt signaling pathway genes in bipolar disorder. Arch Gen Psychiatry (2008) 1.00
Beyond cAMP: The Regulation of Akt and GSK3 by Dopamine Receptors. Front Mol Neurosci (2011) 1.00
Genetic and pharmacological evidence for schizophrenia-related Disc1 interaction with GSK-3. Synapse (2011) 0.99
Functions of GSK-3 Signaling in Development of the Nervous System. Front Mol Neurosci (2011) 0.99
Genome-wide association study of bipolar disorder accounting for effect of body mass index identifies a new risk allele in TCF7L2. Mol Psychiatry (2013) 0.99
Lentivirally mediated GSK-3β silencing in the hippocampal dentate gyrus induces antidepressant-like effects in stressed mice. Int J Neuropsychopharmacol (2010) 0.98
Lithium inhibits Smad3/4 transactivation via increased CREB activity induced by enhanced PKA and AKT signaling. Mol Cell Neurosci (2007) 0.98
Inositol-related gene knockouts mimic lithium's effect on mitochondrial function. Neuropsychopharmacology (2013) 0.97
Cross-species assessments of motor and exploratory behavior related to bipolar disorder. Neurosci Biobehav Rev (2010) 0.97
A role for WNT/β-catenin signaling in the neural mechanisms of behavior. J Neuroimmune Pharmacol (2012) 0.97
GSK-3 in Neurodegenerative Diseases. Int J Alzheimers Dis (2011) 0.97
Neural plasticity and proliferation in the generation of antidepressant effects: hippocampal implication. Neural Plast (2013) 0.96
The Role of Neurotrophins in Major Depressive Disorder. Transl Neurosci (2013) 0.94
New therapeutic targets for mood disorders. ScientificWorldJournal (2010) 0.94
GSK3 Function in the Brain during Development, Neuronal Plasticity, and Neurodegeneration. Int J Alzheimers Dis (2011) 0.94
Molecular actions and clinical pharmacogenetics of lithium therapy. Pharmacol Biochem Behav (2014) 0.94
Functional significance of glycogen synthase kinase-3 regulation by serotonin. Cell Signal (2011) 0.94
NFAT/Fas signaling mediates the neuronal apoptosis and motor side effects of GSK-3 inhibition in a mouse model of lithium therapy. J Clin Invest (2010) 0.92
The Wnt pool of glycogen synthase kinase 3beta is critical for trophic-deprivation-induced neuronal death. Mol Cell Biol (2008) 0.92
Protein Phosphatase 2a and glycogen synthase kinase 3 signaling modulate prepulse inhibition of the acoustic startle response by altering cortical M-Type potassium channel activity. J Neurosci (2010) 0.91
Glycogen Synthase Kinase-3 is an Intermediate Modulator of Serotonin Neurotransmission. Front Mol Neurosci (2011) 0.90
GSK-3/Shaggy regulates olfactory habituation in Drosophila. Proc Natl Acad Sci U S A (2007) 0.90
Regulation by glycogen synthase kinase-3 of inflammation and T cells in CNS diseases. Front Mol Neurosci (2011) 0.90
CDK5 activator protein p25 preferentially binds and activates GSK3β. Proc Natl Acad Sci U S A (2014) 0.89
Second messenger/signal transduction pathways in major mood disorders: moving from membrane to mechanism of action, part I: major depressive disorder. CNS Spectr (2013) 0.88
GSK-3 Mouse Models to Study Neuronal Apoptosis and Neurodegeneration. Front Mol Neurosci (2011) 0.88
Lithium promotes neural precursor cell proliferation: evidence for the involvement of the non-canonical GSK-3β-NF-AT signaling. Cell Biosci (2011) 0.88
Lithium treatment alleviates impaired cognition in a mouse model of fragile X syndrome. Genes Brain Behav (2013) 0.88
Evidence of the cross talk between Wnt and Notch signaling pathways in non-small-cell lung cancer (NSCLC): Notch3-siRNA weakens the effect of LiCl on the cell cycle of NSCLC cell lines. J Cancer Res Clin Oncol (2010) 0.87
Effects of the Ras homolog Rhes on Akt/protein kinase B and glycogen synthase kinase 3 phosphorylation in striatum. Neuroscience (2013) 0.87
Neuroprotective action of lithium in disorders of the central nervous system. Zhong Nan Da Xue Xue Bao Yi Xue Ban (2011) 0.87
Beta-catenin signaling levels in progenitors influence the laminar cell fates of projection neurons. J Neurosci (2009) 0.87
The relationship between affective state and the rhythmicity of activity in bipolar disorder. J Clin Psychiatry (2014) 0.87
Glia and immune cell signaling in bipolar disorder: insights from neuropharmacology and molecular imaging to clinical application. Transl Psychiatry (2014) 0.86
Control of neuronal ion channel function by glycogen synthase kinase-3: new prospective for an old kinase. Front Mol Neurosci (2012) 0.86
Genetical Genomics of Behavior: A Novel Chicken Genomic Model for Anxiety Behavior. Genetics (2016) 0.86
Lithium and genetic inhibition of GSK3beta enhance the effect of methamphetamine on circadian rhythms in the mouse. Behav Pharmacol (2009) 0.85
Inhibiting cytosolic translation and autophagy improves health in mitochondrial disease. Hum Mol Genet (2015) 0.85
Role of Beta-arrestin 2 downstream of dopamine receptors in the Basal Ganglia. Front Neuroanat (2011) 0.85
GSK-3 signaling in developing cortical neurons is essential for radial migration and dendritic orientation. Elife (2014) 0.84
Wnt signaling in neuropsychiatric disorders: ties with adult hippocampal neurogenesis and behavior. Neurosci Biobehav Rev (2014) 0.83
Lithium: the pharmacodynamic actions of the amazing ion. Ther Adv Psychopharmacol (2013) 0.83
Genetic regulation of Nrxn1 [corrected] expression: an integrative cross-species analysis of schizophrenia candidate genes. Transl Psychiatry (2011) 0.83
Investigating tonic Wnt signaling throughout the adult CNS and in the hippocampal neurogenic niche of BatGal and ins-TopGal mice. Cell Mol Neurobiol (2012) 0.82
Lithium, but not valproate, reduces impulsive choice in the delay-discounting task in mice. Neuropsychopharmacology (2013) 0.82
Loss of GSK-3 Causes Abnormal Astrogenesis and Behavior in Mice. Mol Neurobiol (2015) 0.82
Lithium ameliorates autistic-like behaviors induced by neonatal isolation in rats. Front Behav Neurosci (2014) 0.82
Regulation of glycogen synthase kinase-3 in patients with affective disorders. Biol Psychiatry (2007) 0.81
A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci U S A (1996) 11.37
Multiple roles for activated LEF/TCF transcription complexes during hair follicle development and differentiation. Development (1999) 9.82
Behavioral despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther (1977) 8.46
Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation. Nature (2000) 8.37
Mapping Wnt/beta-catenin signaling during mouse development and in colorectal tumors. Proc Natl Acad Sci U S A (2003) 7.60
Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells. Curr Biol (1996) 6.88
GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature (2003) 4.97
GSK-3-selective inhibitors derived from Tyrian purple indirubins. Chem Biol (2003) 4.60
Axonal remodeling and synaptic differentiation in the cerebellum is regulated by WNT-7a signaling. Cell (2000) 4.35
Neural and developmental actions of lithium: a unifying hypothesis. Cell (1989) 4.13
wingless signal and Zeste-white 3 kinase trigger opposing changes in the intracellular distribution of Armadillo. Development (1994) 4.04
Assessing antidepressant activity in rodents: recent developments and future needs. Trends Pharmacol Sci (2002) 4.02
The Drosophila Wnt, wingless, provides an essential signal for pre- and postsynaptic differentiation. Cell (2002) 3.17
Activation of the Wnt signaling pathway: a molecular mechanism for lithium action. Dev Biol (1997) 3.03
Regulation of Akt and glycogen synthase kinase-3 beta phosphorylation by sodium valproate and lithium. Neuropharmacology (2002) 2.64
Molecular targets of lithium action. Annu Rev Pharmacol Toxicol (2001) 2.63
A common mechanism of action for three mood-stabilizing drugs. Nature (2002) 2.58
A proposed test battery and constellations of specific behavioral paradigms to investigate the behavioral phenotypes of transgenic and knockout mice. Horm Behav (1997) 2.47
Lithium activates the serine/threonine kinase Akt-1 and suppresses glutamate-induced inhibition of Akt-1 activity in neurons. Proc Natl Acad Sci U S A (1999) 2.41
Inhibitory phosphorylation of glycogen synthase kinase-3 (GSK-3) in response to lithium. Evidence for autoregulation of GSK-3. J Biol Chem (2003) 2.35
Regulation and localization of tyrosine216 phosphorylation of glycogen synthase kinase-3beta in cellular and animal models of neuronal degeneration. Proc Natl Acad Sci U S A (2000) 2.34
The role of the extracellular signal-regulated kinase signaling pathway in mood modulation. J Neurosci (2003) 2.28
Glycogen synthase kinase 3beta phosphorylation of microtubule-associated protein 1B regulates the stability of microtubules in growth cones. J Cell Sci (1999) 2.10
Inhibition of GSK-3beta leading to the loss of phosphorylated MAP-1B is an early event in axonal remodelling induced by WNT-7a or lithium. J Cell Sci (1998) 2.10
GBP, an inhibitor of GSK-3, is implicated in Xenopus development and oncogenesis. Cell (1998) 2.03
An inactive pool of GSK-3 at the leading edge of growth cones is implicated in Semaphorin 3A signaling. J Cell Biol (2002) 1.78
beta-Catenin associates with the actin-bundling protein fascin in a noncadherin complex. J Cell Biol (1996) 1.70
WNT-7a induces axonal remodeling and increases synapsin I levels in cerebellar neurons. Dev Biol (1997) 1.68
Central role of glycogen synthase kinase-3beta in endoplasmic reticulum stress-induced caspase-3 activation. J Biol Chem (2002) 1.68
Inhibition of GSK-3 selectively reduces glucose-6-phosphatase and phosphatase and phosphoenolypyruvate carboxykinase gene expression. Diabetes (2001) 1.59
Regulation of glycogen synthase kinase 3beta and downstream Wnt signaling by axin. Mol Cell Biol (1999) 1.50
Valproate regulates GSK-3-mediated axonal remodeling and synapsin I clustering in developing neurons. Mol Cell Neurosci (2002) 1.47
Definition of a metal-dependent/Li(+)-inhibited phosphomonoesterase protein family based upon a conserved three-dimensional core structure. Proc Natl Acad Sci U S A (1995) 1.47
Activation of Wnt signaling rescues neurodegeneration and behavioral impairments induced by beta-amyloid fibrils. Mol Psychiatry (2003) 1.47
Lithium inhibits Alzheimer's disease-like tau protein phosphorylation in neurons. FEBS Lett (1997) 1.44
Wnts and TGF beta in synaptogenesis: old friends signalling at new places. Nat Rev Neurosci (2003) 1.37
Lithium attenuates drug-induced hyperactivity in rats. Nature (1971) 1.30
Chronic lithium treatment decreases mutant tau protein aggregation in a transgenic mouse model. J Alzheimers Dis (2003) 1.29
Endophenotypes in bipolar disorder. Am J Med Genet (2002) 1.25
The neurite retraction induced by lysophosphatidic acid increases Alzheimer's disease-like Tau phosphorylation. J Biol Chem (1999) 1.24
Lithium and valproic acid: parallels and contrasts in diverse signaling contexts. Pharmacol Ther (2002) 1.23
Additive effects of lithium and antidepressants in the forced swimming test: further evidence for involvement of the serotoninergic system. Psychopharmacology (Berl) (1994) 1.12
The reliability of the hole-board apparatus. Psychopharmacologia (1975) 1.11
The pharmacokinetic profile of lithium in rat and mouse; an important factor in psychopharmacological investigation of the drug. Neuropharmacology (1986) 1.09
Divergent roles of GSK3 and CDK5 in APP processing. Biochem Biophys Res Commun (2003) 1.03
Wnt factors in axonal remodelling and synaptogenesis. Biochem Soc Symp (1999) 0.95
Lithium research: state of the art. Biol Psychiatry (1990) 0.94
Wnts as retrograde signals for axon and growth cone differentiation. Cell (2000) 0.94
Lithium inhibits aluminum-induced apoptosis in rabbit hippocampus, by preventing cytochrome c translocation, Bcl-2 decrease, Bax elevation and caspase-3 activation. J Neurochem (2002) 0.93
Evidence of the activity of lithium on 5-HT1B receptors in the mouse forced swimming test: comparison with carbamazepine and sodium valproate. Psychopharmacology (Berl) (1999) 0.93
Epi-inositol regulates expression of the yeast INO1 gene encoding inositol-1-P synthase. Mol Psychiatry (2002) 0.89
Lithium and alpha-methyl-p-tyrosine prevent "manic" activity in rodents. Psychopharmacologia (1974) 0.89
Regulation of signal transduction pathways by mood-stabilizing agents: implications for the delayed onset of therapeutic efficacy. J Clin Psychiatry (1996) 0.85
Neurochemical basis of the action of antidepressants on learned helplessness. Behav Neural Biol (1980) 0.84
Influence of ACTH on the effects of imipramine, desipramine and lithium on duration of immobility of rats in the forced swim test. Pharmacol Biochem Behav (2002) 0.83
Reversal of learned helplessness by chronic lithium treatment at a prophylactic level. Braz J Med Biol Res (1993) 0.83
Behavioral characteristics of SART-stressed mice in the forced swim test and drug action. Pharmacol Biochem Behav (1995) 0.81
Lithium attenuates hypokinesia induced by immobilization stress in rats. Prog Neuropsychopharmacol Biol Psychiatry (1995) 0.80
Increased extracellular serotonin level in rat hippocampus induced by chronic citalopram is augmented by subchronic lithium: neurochemical and behavioural studies in the rat. Psychopharmacology (Berl) (2003) 0.80
Time course of clinical-chemical parameters under long-term lithium treatment. Int J Clin Pharmacol Biopharm (1979) 0.79
Effect of lithium and other drugs on the amphetamine chlordiazeposice hyperactivity in mice. Experientia (1975) 0.79
The effect of lithium administration in animal models of depression: a short review. Fundam Clin Pharmacol (1999) 0.79
Role of YAP/TAZ in mechanotransduction. Nature (2011) 11.56
GSK-3: tricks of the trade for a multi-tasking kinase. J Cell Sci (2003) 10.89
Mapping Wnt/beta-catenin signaling during mouse development and in colorectal tumors. Proc Natl Acad Sci U S A (2003) 7.60
Systematic discovery of in vivo phosphorylation networks. Cell (2007) 6.94
A Mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis. Cell (2009) 6.03
MicroRNA control of signal transduction. Nat Rev Mol Cell Biol (2010) 5.74
The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells. Cell (2011) 5.06
GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature (2003) 4.97
A MicroRNA targeting dicer for metastasis control. Cell (2010) 4.81
Functional redundancy of GSK-3alpha and GSK-3beta in Wnt/beta-catenin signaling shown by using an allelic series of embryonic stem cell lines. Dev Cell (2007) 4.39
FAM/USP9x, a deubiquitinating enzyme essential for TGFbeta signaling, controls Smad4 monoubiquitination. Cell (2009) 4.11
Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade. Proc Natl Acad Sci U S A (2004) 3.60
Links between tumor suppressors: p53 is required for TGF-beta gene responses by cooperating with Smads. Cell (2003) 3.45
Proteomic, functional, and domain-based analysis of in vivo 14-3-3 binding proteins involved in cytoskeletal regulation and cellular organization. Curr Biol (2004) 3.45
A mechanical checkpoint controls multicellular growth through YAP/TAZ regulation by actin-processing factors. Cell (2013) 3.17
Transduction of mechanical and cytoskeletal cues by YAP and TAZ. Nat Rev Mol Cell Biol (2012) 3.07
Role of TAZ as mediator of Wnt signaling. Cell (2012) 3.05
Emilin1 links TGF-beta maturation to blood pressure homeostasis. Cell (2006) 2.84
Wnt/beta-catenin signaling acts upstream of N-myc, BMP4, and FGF signaling to regulate proximal-distal patterning in the lung. Dev Biol (2005) 2.73
Germ-layer specification and control of cell growth by Ectodermin, a Smad4 ubiquitin ligase. Cell (2005) 2.66
Nuclear receptor Rev-erbalpha is a critical lithium-sensitive component of the circadian clock. Science (2006) 2.62
IFN-gamma suppresses IL-10 production and synergizes with TLR2 by regulating GSK3 and CREB/AP-1 proteins. Immunity (2006) 2.58
Beta-catenin is required for endothelial-mesenchymal transformation during heart cushion development in the mouse. J Cell Biol (2004) 2.57
Multiple phosphoinositide 3-kinase-dependent steps in activation of protein kinase B. Mol Cell Biol (2002) 2.56
Hypomorphic mutations in PRF1, MUNC13-4, and STXBP2 are associated with adult-onset familial HLH. Blood (2011) 2.55
SHARP1 suppresses breast cancer metastasis by promoting degradation of hypoxia-inducible factors. Nature (2012) 2.46
O2 regulates stem cells through Wnt/β-catenin signalling. Nat Cell Biol (2010) 2.45
beta-Catenin primes organizer gene expression by recruiting a histone H3 arginine 8 methyltransferase, Prmt2. Dev Cell (2010) 2.44
Arginine methylation of Piwi proteins catalysed by dPRMT5 is required for Ago3 and Aub stability. Nat Cell Biol (2009) 2.42
Inhibitory phosphorylation of glycogen synthase kinase-3 (GSK-3) in response to lithium. Evidence for autoregulation of GSK-3. J Biol Chem (2003) 2.35
Wnt/beta-catenin signaling directs multiple stages of tooth morphogenesis. Dev Biol (2007) 2.26
Essential roles for GSK-3s and GSK-3-primed substrates in neurotrophin-induced and hippocampal axon growth. Neuron (2006) 2.23
Unravelling the activation mechanisms of protein kinase B/Akt. FEBS Lett (2003) 2.22
Histone deacetylase is a target of valproic acid-mediated cellular differentiation. Cancer Res (2004) 2.17
Reciprocal requirements for EDA/EDAR/NF-kappaB and Wnt/beta-catenin signaling pathways in hair follicle induction. Dev Cell (2009) 2.17
Glycogen synthase kinase 3alpha-specific regulation of murine hepatic glycogen metabolism. Cell Metab (2007) 2.12
GSK-3 is a master regulator of neural progenitor homeostasis. Nat Neurosci (2009) 2.11
MicroRNA control of Nodal signalling. Nature (2007) 2.09
Tissue-specific role of glycogen synthase kinase 3beta in glucose homeostasis and insulin action. Mol Cell Biol (2008) 2.03
Activation of beta-catenin signaling programs embryonic epidermis to hair follicle fate. Development (2008) 1.96
Convergence of multiple signaling cascades at glycogen synthase kinase 3: Edg receptor-mediated phosphorylation and inactivation by lysophosphatidic acid through a protein kinase C-dependent intracellular pathway. Mol Cell Biol (2002) 1.91
CpG Island microarray probe sequences derived from a physical library are representative of CpG Islands annotated on the human genome. Nucleic Acids Res (2005) 1.89
Glycogen synthase kinase-3--an overview of an over-achieving protein kinase. Curr Drug Targets (2006) 1.88
Functional distinctions of protein kinase B/Akt isoforms defined by their influence on cell migration. Trends Cell Biol (2006) 1.86
Role of glycogen synthase kinase-3 in cell fate and epithelial-mesenchymal transitions. Cells Tissues Organs (2007) 1.77
Deletion of GSK-3beta in mice leads to hypertrophic cardiomyopathy secondary to cardiomyoblast hyperproliferation. J Clin Invest (2008) 1.76
A molecular compendium of genes expressed in multiple myeloma. Blood (2002) 1.70
BMP signaling controls muscle mass. Nat Genet (2013) 1.68
Integration of TGF-beta and Ras/MAPK signaling through p53 phosphorylation. Science (2007) 1.65
DREAM is a critical transcriptional repressor for pain modulation. Cell (2002) 1.63
Role of glycogen synthase kinase-3 in cancer: regulation by Wnts and other signaling pathways. Adv Cancer Res (2002) 1.62
USP15 is a deubiquitylating enzyme for receptor-activated SMADs. Nat Cell Biol (2011) 1.61
Role of phosphoinositide 3-kinase {alpha}, protein kinase C, and L-type Ca2+ channels in mediating the complex actions of angiotensin II on mouse cardiac contractility. Hypertension (2010) 1.59
Chromatin immunoprecipitation in early Xenopus laevis embryos. Dev Dyn (2009) 1.58
Maintenance of hematopoietic stem cells through regulation of Wnt and mTOR pathways. Nat Med (2012) 1.58
IL-17 receptor signaling inhibits C/EBPbeta by sequential phosphorylation of the regulatory 2 domain. Sci Signal (2009) 1.57
When pathways collide: collaboration and connivance among signalling proteins in development. Nat Rev Mol Cell Biol (2010) 1.57
The Wnt/beta-catenin pathway regulates Gli-mediated Myf5 expression during somitogenesis. Development (2006) 1.55
Akt1 and akt2 play distinct roles in the initiation and metastatic phases of mammary tumor progression. Cancer Res (2009) 1.53
Pivotal role for glycogen synthase kinase-3 in hematopoietic stem cell homeostasis in mice. J Clin Invest (2009) 1.52
Unique and overlapping functions of GSK-3 isoforms in cell differentiation and proliferation and cardiovascular development. J Biol Chem (2008) 1.49
Problems with co-funding in Canada. Science (2005) 1.48
Retracted GSK-3beta in mouse fibroblasts controls wound healing and fibrosis through an endothelin-1-dependent mechanism. J Clin Invest (2008) 1.46
Abnormalities in brain structure and behavior in GSK-3alpha mutant mice. Mol Brain (2009) 1.44
Negative regulation of mixed lineage kinase 3 by protein kinase B/AKT leads to cell survival. J Biol Chem (2002) 1.43
Serum and glucocorticoid-regulated protein kinases: variations on a theme. J Cell Biochem (2006) 1.42
Cellular plasticity cascades in the pathophysiology and treatment of bipolar disorder. Neuropsychopharmacology (2007) 1.41
Genetic deficiency of glycogen synthase kinase-3beta corrects diabetes in mouse models of insulin resistance. PLoS Biol (2008) 1.40
Beta-catenin/Tcf-regulated transcription prior to the midblastula transition. Development (2002) 1.40
Beta-catenin controls differentiation of the retinal pigment epithelium in the mouse optic cup by regulating Mitf and Otx2 expression. Development (2009) 1.39
Glycogen synthase kinase-3beta induces neuronal cell death via direct phosphorylation of mixed lineage kinase 3. J Biol Chem (2007) 1.37
Negative control of Smad activity by ectodermin/Tif1gamma patterns the mammalian embryo. Development (2010) 1.35
The Frizzled family: receptors for multiple signal transduction pathways. Genome Biol (2004) 1.34
GSK-3 and Wnt Signaling in Neurogenesis and Bipolar Disorder. Front Mol Neurosci (2012) 1.34
Glycogen synthase kinase-3beta regulates post-myocardial infarction remodeling and stress-induced cardiomyocyte proliferation in vivo. Circ Res (2010) 1.33
Dose-dependent Smad1, Smad5 and Smad8 signaling in the early mouse embryo. Dev Biol (2006) 1.32
Association of valproate-induced teratogenesis with histone deacetylase inhibition in vivo. FASEB J (2005) 1.31
GSK-3beta controls osteogenesis through regulating Runx2 activity. PLoS One (2007) 1.29
Validating GSK3 as an in vivo target of lithium action. Biochem Soc Trans (2009) 1.27
Cooperating pre-T-cell receptor and TCF-1-dependent signals ensure thymocyte survival. Blood (2005) 1.25
Lithium and valproic acid: parallels and contrasts in diverse signaling contexts. Pharmacol Ther (2002) 1.23
Targeting triple negative breast cancer: is p53 the answer? Cancer Treat Rev (2013) 1.23
CD28-dependent activation of protein kinase B/Akt blocks Fas-mediated apoptosis by preventing death-inducing signaling complex assembly. J Exp Med (2002) 1.22
PP2A:B56epsilon is required for Wnt/beta-catenin signaling during embryonic development. Development (2003) 1.21
Arginine methylation of vasa protein is conserved across phyla. J Biol Chem (2010) 1.21
Glycogen synthase kinase-3 is essential for β-arrestin-2 complex formation and lithium-sensitive behaviors in mice. J Clin Invest (2011) 1.20
CD4+ and CD8+ T cell survival is regulated differentially by protein kinase Ctheta, c-Rel, and protein kinase B. J Immunol (2007) 1.18
The active form of glycogen synthase kinase-3beta is associated with granulovacuolar degeneration in neurons in Alzheimer's disease. Acta Neuropathol (2001) 1.15
Developmental phenotypes and reduced Wnt signaling in mice deficient for pygopus 2. Genesis (2007) 1.15
Phosphoinositide-dependent phosphorylation of PDK1 regulates nuclear translocation. Mol Cell Biol (2005) 1.12
Glycogen synthase kinase-3beta heterozygote knockout mice as a model of findings in postmortem schizophrenia brain or as a model of behaviors mimicking lithium action: negative results. Behav Pharmacol (2008) 1.12
Effect of Inhibiting Histone Deacetylase with Short-Chain Carboxylic Acids and Their Hydroxamic Acid Analogs on Vertebrate Development and Neuronal Chromatin. ACS Med Chem Lett (2010) 1.11
SANE, a novel LEM domain protein, regulates bone morphogenetic protein signaling through interaction with Smad1. J Biol Chem (2002) 1.11
GSK3: an in-Toll-erant protein kinase? Nat Immunol (2005) 1.11
Wnt-1 but not epidermal growth factor induces beta-catenin/T-cell factor-dependent transcription in esophageal cancer cells. Cancer Res (2002) 1.10
Glycogen synthase kinase 3beta is a negative regulator of growth factor-induced activation of the c-Jun N-terminal kinase. J Biol Chem (2004) 1.09
Assessment of social interaction behaviors. J Vis Exp (2011) 1.09
NF-kappaB couples protein kinase B/Akt signaling to distinct survival pathways and the regulation of lymphocyte homeostasis in vivo. J Immunol (2005) 1.08